AbCellera Biologics Plans To Use Net Proceeds From Offering to Fund Continued Research, Development and Clinical Advancement of Its Internal Pipeline >ABCL

Dow Jones2026/08/13 04:11

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Pundit Says This News Is Highly Bullish for Ripple and XRP

TimesTabloid•2026/09/13 11:00

Researcher: If You Hold XRP, Don’t Make This Mistake

TimesTabloid•2026/09/13 10:00

Clarity Act News: Why Rep. Bryan Steil Says the Votes Are Already There

Coinpedia•2026/09/13 07:30

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM

Reuters•2026/09/13 07:28